CEO of Amplia Therapeutics, a Melbourne, Australia, based biotech developing a pipeline of small molecule FAK inhibitors for cancer and fibrotic diseases. Our lead asset is narmafotinib currently in a Phase 2a trial in pancreatic cancer (NCT05355298).